Helix BioPharma Delays Financial Filings Update
Company Announcements

Helix BioPharma Delays Financial Filings Update

Helix Biopharma Corp. (TSE:HBP) has released an update.

Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has announced a delay in filing its interim financial statements, originally due on March 1, 2024. The company has requested a voluntary management cease trade order, which, if approved, will restrict its executives from trading shares but will not affect public trading. Helix reassures that there are no undisclosed material changes or information and aims to complete the filings by May 18, 2024.

For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma Announces Share Consolidation Plan
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma Secures Funding Through Shares
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma’s Financial Update Clears Regulatory Hurdle
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App